# Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations

> **NCT06118658** · PHASE2 · NOT_YET_RECRUITING · sponsor: **China Medical University, China** · enrollment: 30 (estimated)

## Conditions studied

- Gastric
- Colorectal Adenocarcinoma

## Interventions

- **DRUG:** tislelizumab

## Key facts

- **NCT ID:** NCT06118658
- **Lead sponsor:** China Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06118658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06118658, "Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06118658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*